Recent studies from transplantable solid tumor models have indicated a direct role of exogenous IL-33 in promoting antitumor CD8+ T cell immunity using either IL-33 transgenic mice [20], IL-33 DNA as vaccine adjuvant [22], or IL-33 expressing tumor cells [21]. The gene discussed is CD8A; the disease is neoplasm.